Saved Results

No results saved yet.

Enter a patient name and hit Save on a result.

Clinical calculator summary

CPS+EG Score

The Clinical-Pathologic Stage + Estrogen/Grade (CPS+EG) staging system improves prognostic stratification for patients with breast cancer treated with neoadjuvant chemotherapy.

Evidence-based context for fast calculator use

Purpose:
CPS+EG score estimates distant metastasis-free survival in breast cancer after neoadjuvant chemotherapy to stratify post-treatment prognosis.
Population:
patients undergoing breast cancer risk, staging, pathology, recurrence, or treatment-benefit assessment
Factors:
Clinical Stage, Pathologic Stage, Estrogen ReceptorStatus, Nuclear Grade
Reference:
Mittendorf EA, Jeruss JS, Tucker SL, et al. Validation of a novel staging system for disease-specific survival in patients with breast cancer treated with neoadjuvant chemotherapy. J Clin Oncol. 2011;29(15):1956-1962.
HomeCPS+EG Score
Pin your most used calculators here by clicking the star in the dropdown.

CPS+EG Score

Clinical Context & Background

The Clinical-Pathologic Stage + Estrogen/Grade (CPS+EG) staging system improves prognostic stratification for patients with breast cancer treated with neoadjuvant chemotherapy. It incorporates both the presenting clinical stage and the final pathologic stage, along with biologic factors.
Primary Source EvidenceMittendorf EA, Jeruss JS, Tucker SL, et al. Validation of a novel staging system for disease-specific survival in patients with breast cancer treated with neoadjuvant chemotherapy. J Clin Oncol. 2011;29(15):1956-1962.
Formula Logic
Score = Clinical Stage + Pathologic Stage + ER Status + Nuclear Grade

Reference Data

Total Score5-Year Distant Metastasis-Free Survival (DMFS)
0> 90%
1~ 85-90%
2~ 75-85%
3~ 60-70%
4~ 45-55%
5 - 6< 30%

Clinical Workflow

Use, Interpret, And Continue The Patient Pathway

Expand for workflow guidance, limitations, examples, and related next steps.

When To Use

  • Use CPS+EG Score when cPS+EG score estimates distant metastasis-free survival in breast cancer after neoadjuvant chemotherapy to stratify post-treatment prognosis.
  • Confirm that the patient, diagnosis, disease phase, and available inputs match the cited model before calculation.

How To Interpret

  • Interpret the displayed result using the calculator-specific formula and reference table, spanning 0 through 5 - 6.
  • A boundary result should prompt input verification and clinical review rather than false precision.

What To Do Next

  • Integrate the result with invasive versus in-situ status, stage, receptor biology, treatment timing, genomic testing, comorbidity, and patient goals.
  • Document the inputs, result, timing, and clinical context so the assessment can be reproduced.

Limitations

  • Do not interchange screening-risk, DCIS, invasive prognosis, genomic, and post-neoadjuvant tools.
  • The result supports clinician judgment and does not independently determine treatment.

Validated Population

patients undergoing breast cancer risk, staging, pathology, recurrence, or treatment-benefit assessment

How to apply this result

For a representative case, verify Clinical Stage, Pathologic Stage, Estrogen ReceptorStatus, calculate the result, and confirm that its classification matches the highlighted reference band before continuing the disease-specific pathway.

Breast Cancer hubContinue to related calculators and clinical workflow resources.

Share This Calculator

Share:

Related Tools

BI-RADS Score (Breast)Nottingham Prognostic Index (NPI)MSKCC DCIS Nomogram — Breast Cancer DCIS Recurrence Risk Calculator

Frequently Asked Questions

When should CPS+EG Score be used?

Use it for patients undergoing breast cancer risk, staging, pathology, recurrence, or treatment-benefit assessment when all required inputs and the intended clinical setting are confirmed.

Can CPS+EG Score determine treatment by itself?

No. Interpret the result with the cited evidence, complete clinical assessment, current guidelines, and patient-specific goals.

Evidence-based oncology decision support. Verify with clinical guidelines.